Stimulants—Including Cocaine

  • Marc A. Schuckit
Part of the Critical Issues in Psychiatry book series (CIPS)


Stimulants are widely prescribed and greatly misused medications that have few bona fide medical uses. It is important that the clinician know these drugs well, as their misuse can mimic a variety of medical and psychiatric syndromes.


Neuroleptic Malignant Syndrome Cocaine Abuser Biological Psychiatry Cocaine Dependence Stimulant Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    King, G. R., & Ellinwood, E. H. Amphetamines and other stimulants. In J. H. Lowinson, P. Ruiz, R. B. Mill-man, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 207–223.Google Scholar
  2. 2.
    Chait, L. D. Factors influencing the reinforcing and subjective effects of ephedrine in humans. Psychopharmacology 113:381–387, 1994.PubMedGoogle Scholar
  3. 3.
    Ellinwood, E. H., & Lee, T. H. Psychopathology and treatment of amphetamine abuse. In H. Rommelspocher & M. Schuckit (Eds.), Bailliere’s clinical psychiatry: Drugs of abuse. London: Bailliere Tindall, 1996, pp. 487–501.Google Scholar
  4. 4.
    Gold, M. S., & Herkov, M. J., The pharmacology of cocaine, crack and other stimulants. In A. W. Graham, T. K. Schultz, & B. B. Wilford (Eds.), Principles of addiction medicine (2nd ed.). Chevy Chase, MD: American Society of Addiction Medicine, 1998, pp. 137–146.Google Scholar
  5. 5.
    Woody, G. E., Mercer, D. E., & Auriacombe, M. Cocaine use disorders. In H. Rommelspocher & M. Schuckit (Eds.), Bailliere’s clinical psychiatry: Drugs of abuse. London: Bailliere Tindall, 1996, pp. 461–479.Google Scholar
  6. 6.
    O’Brien, C. P. Drug addiction and drug abuse. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 557–577.Google Scholar
  7. 7.
    Gold, M. S. Cocaine (and crack): Clinical aspects. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 181–199.Google Scholar
  8. 8.
    Gold, M. S., & Miller, N. S. Cocaine (and crack): Neurobiology. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 166–181.Google Scholar
  9. 9.
    Klee, H. (Ed.). Amphetamine misuse: International perspectives on current trends. Amsterdam: Harwood Academic Publishers, 1997.Google Scholar
  10. 10.
    Sato, M., Chen, C. C., Akiyama, S., & Otsuki, S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biological Psychiatry 18:429–440, 1983.PubMedGoogle Scholar
  11. 11.
    Winger, G., Hofmann, F. G., & Woods, J. H. A handbook on drug and alcohol abuse (3rd ed.). New York: Oxford University Press, 1992, pp. 132–149.Google Scholar
  12. 12.
    Cho, A. K. Ice: A new dosage form of an old drug. Science 249:631–634, 1990.PubMedGoogle Scholar
  13. 13.
    Kaufman, M. J., Levin, J. M., Ross, M. H., et al. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. Journal of the American Medical Association 279:376–380, 1998.PubMedGoogle Scholar
  14. 14.
    Morgan, J. P. Designer drugs. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 264–269.Google Scholar
  15. 15.
    Griffiths, P. Qat use in London: a study of qat use among a sample of Somalis living in London. United Kingdom: Central Drugs Prevention Unit, 1998.Google Scholar
  16. 16.
    Al-Meshal, I. A. The toxicity of khat in mice. Journal of Substance Abuse 3:107–115, 1991.PubMedGoogle Scholar
  17. 17.
    Griffiths, P., Gossop, M., Wickenden, S., et al. A transcultural pattern of drug use: Qat (khat) in the UK. British Journal of Psychiatry, 170:281–284, 1997.PubMedGoogle Scholar
  18. 18.
    O’Dell, L. E., Sussman, A. N., Meyer, K. L., & Neisewander, J. L. Behavioral effects of psychomotor stimulant infusions into amygdaloid nuclei. Neuropsychopharmacology 20:591–602, 1999.PubMedGoogle Scholar
  19. 19.
    Kovar, K. A., Gouzoulis, E., & Hermle, L. Amphetamines. In H. Rommelspocher & M. Schuckit (Eds.), Bailliere’s clinical psychiatry: Drugs of abuse. London: Bailliere Tindall, 1996, pp. 479–488.Google Scholar
  20. 20.
    Jaffe, J. H. Amphetamine (or amphetaminelike)-related disorders. In H. I. Kaplan & B. J. Saddock (Eds.), Comprehensive textbook of psychiatry (6th ed.). Baltimore, MD: Williams & Wilkins, 1995, pp. 791–799.Google Scholar
  21. 21.
    Mendelson, J. H., & Mello, N. K. Cocaine and other commonly abused drugs. In A. S. Fauci, E. Braunwald, K. J. Isselbacher, et al. (Eds.), Harrison’s principles of internal medicine (14th ed.). New York: McGraw-Hill, 1998, pp. 2512–2516.Google Scholar
  22. 22.
    Weissman, N. J., Tighe, J. F. Jr., Gottdiener, J. S., & Gwynne, J. T. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. New England Journal of Medicine 339:725–732, 1998.PubMedGoogle Scholar
  23. 23.
    Volkow, N. D., Wang, G.-J., Fowler, J. S., et al. Effects of methylphenidate on regional brain glucose metabolism in humans: Relationship to dopamine D2 receptors. American Journal of Psychiatry 154:50–55, 1997.PubMedGoogle Scholar
  24. 24.
    Volkow, N. D., Wang, G. J., Fowler, J. S., et al. Dopamine transported occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry 155:1325–1331, 1998.PubMedGoogle Scholar
  25. 25.
    Irwin, M. Cocaine and amphetamine: Psychostimulant abuse. In T. Widiger, A. Frances, H. Pincus, M. First, & W. Davis (Eds.), The DSM-IV Sourcebook, Vol 1. Washington, DC: American Psychiatric Press, 1994, pp. 169–179.Google Scholar
  26. 26.
    American Psychiatric Association. The diagnostic and statistical manual of mental disorders (4th ed. Washington, DC: American Psychiatric Press, 1994.Google Scholar
  27. 27.
    Little, K. Y., McLayghlin, D. P., Zhang, L., et al. Brain dopamine transporter messenger RNA and binding sites in cocaine users. Archives of General Psychiatry 55:793–799, 1998.PubMedGoogle Scholar
  28. 28.
    Segal, D. S., & Kuczenski, R. An escalating dose “binge” model of amphetamine psychosis: Behavioral and neurochemical characteristics. The Journal of Neuroscience 17:2551–2566, 1997.PubMedGoogle Scholar
  29. 29.
    Volkow, N. D., Wang, G.-J., Fowler, J. S., et al. Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: A PET study. American Journal of Psychiatry 155:200–206, 1998.PubMedGoogle Scholar
  30. 30.
    Volkow, N. D., Wang, G.-J., Fowler, J. S., et al. Cocaine uptake is decreased in the brain of detoxified cocaine abusers. Neuropsychopharmacology 14:159–168, 1996.PubMedGoogle Scholar
  31. 31.
    Little, K. Y., Zhang, L., Desmond, T., et al. Striatal dopaminergic abnormalities in human cocaine users. American Journal of Psychiatry 156:238–245, 1999.PubMedGoogle Scholar
  32. 32.
    McCreary, A. C., & Cunningham, K. A. Effects of the 5-HT2C/2B antagonist SB 206553 on hyperactivity induced by cocaine. Neuropsychopharmacology 20:556–564, 1999.PubMedGoogle Scholar
  33. 33.
    Buydens-Branchey, L., Branchey, M., Hudson, J., et al. Serotonergic function in cocaine addicts: Prolactin responses to sequential D, L-fenfluramine challenges. Biological Psychiatry 45:1300–1306, 1999.PubMedGoogle Scholar
  34. 34.
    Betancur, C., Cabrera, R., De Kloet, E. R., et al. Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology 19:322–332, 1998.PubMedGoogle Scholar
  35. 35.
    Pearlson, G. D., Jeffery, P. J., Harris, G. J., et al. Correlation of acute cocaine-induced changes in local cerebral blood flow with subjective effects. American Journal of Psychiatry 150:495–497, 1993.PubMedGoogle Scholar
  36. 36.
    Johnson, B., Lamki, L., Fang, B., et al. Demonstration of dose-dependent global and regional cocaine-induced reductions in brain blood flow using a novel approach to quantitative single photon emission computerized tomography. Neuropsychopharmacology 18:377–384, 1998.PubMedGoogle Scholar
  37. 37.
    Mathew, R. J., Wilson, W. H., Lowe, J. V., & Humphries, D. Acute changes in cranial blood flow after cocaine hydrochloride. Biological Psychiatry 40:609–616, 1996.PubMedGoogle Scholar
  38. 38.
    Schlaepfer, T. E., Pearlson, G. D., Wong, D. F., et al. PET study of competition between intravenous cocaine and [11C]Raclopride at dopamine receptors in human subjects. American Journal of Psychiatry 154:1209–1213, 1997.PubMedGoogle Scholar
  39. 39.
    Buydens-Branchey, L., Branchey, M., Fergeson, P., et al. The metachlorophenylpiperazine challenge test in cocaine addicts: Hormonal and psychological responses. Biological Psychiatry 41:1071–1086, 1997.PubMedGoogle Scholar
  40. 40.
    Malison, R. T., Best, S. E., van Dyck, C. H., et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I]b-CIT SPECT. American Journal of Psychiatry 155:832–834, 1998.PubMedGoogle Scholar
  41. 41.
    Childress, A. R., Mozley, P. D., McElgin, W., et al. Limbic activation during cue-induced cocaine craving. American Journal of Psychiatry 156:11–18. 1999.PubMedGoogle Scholar
  42. 42.
    Volkow, N. D., Fowler, J. S., & Wolf, A. P. Use of PET to study cocaine in the human brain. In R. Rapaka, A. Makriyannis, & M. J. Kuhar (Eds.), Emerging technologies and new directions in drug abuse research. NIDA Research Monograph 112:168-179, 1991.Google Scholar
  43. 43.
    Wu, J. C., Bell, K., Najafi, A., et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 17:402–409, 1997.PubMedGoogle Scholar
  44. 44.
    Roy, M., Roy, A., Smelson, D., et al. Reduced blue cone electroretinogram in withdrawn cocaine dependent patients: A replication. Biological Psychiatry 42:631–633, 1997.PubMedGoogle Scholar
  45. 45.
    Giros, B., Jaber, M., Jones, S. R., et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612, 1996.PubMedGoogle Scholar
  46. 46.
    Seale, T. W Genetic differences in response to cocaine and stimulant drugs. In J. C. Crabbe & R. A. Harris (Eds.), The genetic basis of alcohol and drug actions. New York: Plenum Press, 1991, pp. 279–321.Google Scholar
  47. 47.
    Morgan, M. J., Cascella, N. G., Stapleton, J. M., et al. Sensitivity to subjective effects of cocaine in drug abusers: Relationship to cerebral ventricle size. American Journal of Psychiatry 150:1712–1717, 1993.PubMedGoogle Scholar
  48. 48.
    Kendler, K. S., & Prescott, C. A. Cocaine use, abuse and dependence in a population-based sample of female twins. British Journal of Psychiatry 173:345–350, 1998.PubMedGoogle Scholar
  49. 49.
    Negus, S. S., Gatch, M. B., & Mello, N. K. Effects of mu opioid agonists alone and in combination with cocaine and D-amphetamine in rhesus monkeys trained to discriminate cocaine. Neuropsychopharmacology 18:325–338, 1998.PubMedGoogle Scholar
  50. 50.
    Pecins-Thompson, M., & Peris, J. Behavioral and neurochemical changes caused by repeated ethanol and cocaine administration. Psychopharmacology 110:443–450, 1993.PubMedGoogle Scholar
  51. 51.
    Higgins, S. T., Rush, C. R., Hughes, J. H., et al. Effects of cocaine and alcohol, alone and in combination, on human learning and performance. Journal of the Experimental Analysis of behavior 58:87–105, 1992.PubMedGoogle Scholar
  52. 52.
    Randall, T. Cocaine, alcohol mix in body to form even longer lasting, more lethal drug. Journal of the American Medical Association 267: 1043–1044, 1992.PubMedGoogle Scholar
  53. 53.
    McCance-Katz, E. F., Kosten, T. R., & Jatlow, P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone—A multiple-dose study. Biological Psychiatry 44:250–259, 1998.PubMedGoogle Scholar
  54. 54.
    Cocores, J., Pottash, A. C., & Gold, M. S. Cocaine. In N. S. Miller (Ed.), Comprehensive handbook of drug and alcohol addiction. New York: Marcel Dekker, 1991, pp. 341–352.Google Scholar
  55. 55.
    Fischman, M. W., & Foltin, R. W. A comparison of the effects of smoked and intravenous cocaine in humans. Paper presented at the ACNP Annual Meeting, Maui, Hawaii, December 12, 1989.Google Scholar
  56. 56.
    Zwerling, C., Ryan, J., & Orav, E. J. The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. Journal of the American Medical Association 264:2639–2643, 1990.PubMedGoogle Scholar
  57. 57.
    Higgins, S. T., Bickel, W. K., Hughes, J. R., et al. Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology 102:451–458, 1990.PubMedGoogle Scholar
  58. 58.
    Salloum, I. M., Daley, D. C., Cornelius, J. R., et al. Disproportionate lethality in psychiatric patients with concurrent alcohol and cocaine abuse. American Journal of Psychiatry 153:953–955, 1996.PubMedGoogle Scholar
  59. 59.
    Byck, R. The effects of cocaine on complex performance in humans. Alcohol, Drugs, and Driving 3:9–11, 1987.Google Scholar
  60. 60.
    Mendelson, J. H., Sholar, M., Mello, N. K., et al. Cocaine tolerance: Behavioral, cardiovascular, and neu-roendochrine function in men. Neuropsychopharmacology 18:263–271, 1998.PubMedGoogle Scholar
  61. 61.
    Woolverton, W. L., Kandel, D., & Schuster, C. R. Tolerance and cross-tolerance to cocaine and D-amphetamine. Journal of Pharmacological and Experimental Therapeutics 205:525–535, 1979.Google Scholar
  62. 62.
    Fraioli, S., Crombag, H. S., Badiani, A., & Robinson, T. E. Susceptibility to amphetamine-induced locomotor sensitization is modulated by environmental stimuli. Neuropsychopharmacology 20:533–541, 1999.PubMedGoogle Scholar
  63. 63.
    Huang, Y.-H., Tsai, S.-J., Wang, Y.-C., et al. Differential development of the enhanced metabolic response during amphetamine sensitization. Neuropsychobiology 36:177–181, 1997.PubMedGoogle Scholar
  64. 64.
    White, F. J., Joshi, A., Koeltzow, T. E., & Hu, X.-T. Dopamine receptor antagonists fail to prevent induction of cocaine sensitization. Neuropsychopharmacology 18:26–40, 1998.PubMedGoogle Scholar
  65. 65.
    Friedman, A. S., & Cacciola, J. Validation of the criteria for DSM diagnoses of cocaine abuse and cocaine dependence. American Journal of Drug and Alcohol Abuse 24:169–177, 1998.PubMedGoogle Scholar
  66. 66.
    American Psychiatric Association. The diagnostic and statistical manual of mental disorders (3rd ed. rev.). Washington, DC: American Psychiatric Press, 1987.Google Scholar
  67. 67.
    Schuckit, M. A., Daeppen, J.-B., Danko, G. P., et al. The clinical implications for four drugs of the DSM-IV distinction between substance dependence with and without a physiological component. American Journal of Psychiatry 156:41–49, 1999.PubMedGoogle Scholar
  68. 68.
    Maas, L. C., Lukas, S. E., Kaufman, M. J., et al. Functional magnetic resonance imaging of human brain activation during cue-induced cocaine craving. American Journal of Psychiatry 155:124–126, 1998.PubMedGoogle Scholar
  69. 69.
    Liu, X., Vaupel, D. B., Grant, S., & London, E. D. Effect of cocaine-related environmental stimuli on the spontaneous electroencephalogram in polydrug abusers. Neuropsychopharmacology 19:10–17, 1998.PubMedGoogle Scholar
  70. 70.
    Herning, R. I., Guo X., Better, W E., et al. Neurophysiological signs of cocaine dependence: Increased electroencephalogram beta during withdrawal. Biological Psychiatry 41:1087–1094, 1997.PubMedGoogle Scholar
  71. 71.
    Prichep, L. S., Alper, K. R., Kowalik, S., et al. Quantitative electroencephalographic characteristics of crack cocaine dependence. Biological Psychiatry 40:986–993, 1996.PubMedGoogle Scholar
  72. 72.
    Alper, K. R., Prichep, L. S., Kowalik, S., et al. Persistent EEG abnormalities in crack cocaine users at 6 months of drug abstinence. Neuropsychopharmacology 19:1–9, 1998.PubMedGoogle Scholar
  73. 73.
    Tran-Nguyen, T. L., Fuchs, R. A., Coffey, G. P., et al. Time-dependent changes in cocaine-seeking behavior and extracellular dopamine levels in the amygdala during cocaine withdrawal. Neuropsychopharmacology 19:48–59, 1998.PubMedGoogle Scholar
  74. 74.
    Mitler, M. M., Guilleminault, E., Harsh, C., & Hirshkowitz, M. Randomized trial of moodafinil for the treatment of narcolepsy. Annals of Neurology 43:88–97, 1998.Google Scholar
  75. 75.
    Matochik, J. A., Nordahl, T. E., Gross, M., et al. Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology 8:377–386, 1993.PubMedGoogle Scholar
  76. 76.
    Biederman, J., Wilens, T. E., Mick, E., et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biological Psychiatry 44:269–273, 1998.PubMedGoogle Scholar
  77. 77.
    Stunkard, A. J., Stinnett, J. L., & Smoller, J. W. Psychological and social aspects of the surgical treatment of obesity. American Journal of Psychiatry 143:417–429, 1986.PubMedGoogle Scholar
  78. 78.
    McCann, U. D., Seiden, L. S., Rubin, L. J., & Ricaurte, G. A. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence. Journal of the American Medical Association 278:666–672, 1997.PubMedGoogle Scholar
  79. 79.
    Palumbo, J. M., Gold, M. S., & Pottash, A. C. Cocaine: Epidemiology. In N.S. Miller (Ed.), Comprehensive handbook of drug and alcohol addiction. New York: Marcel Dekker, 1991, pp. 125–130.Google Scholar
  80. 80.
    Angrist, B. M., & Gershon, S. Psychiatric sequelae of amphetamine use. In R. I. Shader (Ed.), Psychiatric complications of medical drugs. New York: Raven Press, 1972, pp. 23–35.Google Scholar
  81. 81.
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National household survey on drug abuse: Population estimates 1997. Rockville, MD: U.S. Department of Health and Human Services, 1998.Google Scholar
  82. 82.
    Johnston, L. D., O’Malley, P. M., & Bachman, J. G. National survey results on drug use from the Monitoring the Future study, 1975–1997, Vol. I, Secondary School Students. Rockville, MD: National Institute on Drug Abuse, U.S. Department of Health and Human Services, 1998.Google Scholar
  83. 83.
    Crits-Christoph, P., & Siqueland, L. Psychosocial treatment for drug abuse. Archives of General Psychiatry 53:149–156, 1996.Google Scholar
  84. 84.
    Royo-Bordonada, M. A., Cid-Ruzafa, J., Martin-Moreno, J. M., & Guallar, E. Drug and alcohol use in Spain: Consumption habits, attitudes and opinions. Public Health 111:277–284, 1997.PubMedGoogle Scholar
  85. 85.
    Florenzano, R., Pino, P., & Marchandon, A. Risk behavior in adolescent students in Santiago de Chile. Re-vista Medica de Chile 121:462–469, 1993.Google Scholar
  86. 86.
    Mora, M. E., Villatoro, J., & Rojas, E. Drug use among students in Mexico’s northern border states. In Department of Health and Human Services, Epidemiologic trends in drug abuse. Washington, DC: U.S. Government Printing Office, 1996, pp. 367–375.Google Scholar
  87. 87.
    Griffin, M. L., Weiss, R. D., Mirin, S. M., & Lange, U. A comparison of male and female cocaine abusers. Archives of General Psychiatry 46:122–126, 1989.PubMedGoogle Scholar
  88. 88.
    Vincent, N., Shoobridge, J., Ask, A., et al. Characteristics of amphetamine users seeking information, help and treatment in Adelaide, South Australia. Drug and Alcohol Review 18:63–73, 1999.Google Scholar
  89. 89.
    Carroll, K. M., & Rounsaville, B. J. Contrast of treatment-seeking and untreated cocaine abusers. Archives of General Psychiatry 49:464–471, 1992.PubMedGoogle Scholar
  90. 90.
    Komura, K., Hirai, S., & Sasahara, M. Treatment of methamphetamine-related disorders. In S. Fukui (Ed.), Cocaine and methamphetamine. Tokyo: Drug Abuse Prevention Center, 1991, pp. 346–354.Google Scholar
  91. 91.
    Schuckit, M. A. Educating yourself about alcohol and drugs. New York: Plenum Publishing Co., 1998.Google Scholar
  92. 92.
    Schuckit, M. A. Alcohol, anxiety, and depressive disorders. Alcohol Health & Research World 20:81–85, 1996.Google Scholar
  93. 93.
    Tardiff, K., Marzuk, P. M., Leon, A. C., et al. Accidental fatal drug overdoses in New York City: 1990–1992. American Journal of Drug and Alcohol Abuse 22:135–146, 1996.PubMedGoogle Scholar
  94. 94.
    Kosten, T. R., & Kleber, H. D. Sudden death in cocaine abusers: Relation to neuroleptic malignant syndrome. Lancet 1:1198–1199, 1987.PubMedGoogle Scholar
  95. 95.
    McKelway, R., Vieweg, V., & Westerman, P. Sudden death from acute cocaine intoxication in Virginia in 1988. American Journal of Psychiatry 147:1667–1669, 1990.PubMedGoogle Scholar
  96. 96.
    Kosten, T., & Kleber, H. Rapid death during cocaine abuse: A variant of the neuroleptic malignant syndrome? American Journal of Drug and Alcohol Abuse 14:335–346, 1988.PubMedGoogle Scholar
  97. 97.
    Witkin, J. M., Johnson, R. E., Jaffe, J. H., et al. The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine. Drug and Alcohol Dependence 27:177–184, 1991.PubMedGoogle Scholar
  98. 98.
    Catravas, J. D., Waters, I. W., Walz, M. A., & Davis, W. M. Antidotes for cocaine poisoning. New England Journal of Medicine 297:1238, 1977.PubMedGoogle Scholar
  99. 99.
    Angrist, M. D., Less, H. K., & Gershon, S. The antagonism of amphetamine-induced symptomatology by a neuroleptic. American Journal of Psychiatry 131:817–819, 1974.PubMedGoogle Scholar
  100. 100.
    Rappolt, R. T. Propranolol in cocaine toxicity. Lancet 2:640–641, 1976.PubMedGoogle Scholar
  101. 101.
    Espelin, D. E., & Done, A. K. Amphetamine poisoning: Effectiveness of chlorpromazine. New England Journal of Medicine 278:1361–1365, 1978.Google Scholar
  102. 102.
    Weddington, W. W., Brown, B. S., Haertzen, C. A., et al. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study. Archives of General Psychiatry 47:861–868, 1990.PubMedGoogle Scholar
  103. 103.
    Weiss, R. D., Hufford, C., & Mendelson, J. H. Serum prolactin levels and treatment outcome in cocaine dependence. Biological Psychiatry 35:573–574, 1994.PubMedGoogle Scholar
  104. 104.
    Markou, A., & Koob, G. E. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsy-chopharmacology 4:17–26, 1991.Google Scholar
  105. 105.
    Swerdlow, N. R., Hauger, R., Irwin, M., et al. Endocrine, immune, and neurochemical changes in rats during withdrawal from chronic amphetamine intoxication. Neuropsychopharmacology 5:23–31, 1991.PubMedGoogle Scholar
  106. 106.
    Gawin, F. H., & Kleber, H. D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Archives of General Psychiatry 43:107–133, 1986.PubMedGoogle Scholar
  107. 107.
    Bauer, L. Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients. Alcoholism: Clinical and Experimental Research 20:1196–1201, 1996.Google Scholar
  108. 108.
    McKetin, R., & Solowij, N. Event-related potential indices of auditory selective attention in dependent amphetamine users. Biological Psychiatry 45:1488–1497, 1999.PubMedGoogle Scholar
  109. 109.
    Bartzokis, G., Beckson, M., Hance, D. B., et al. Magnetic resonance imaging evidence of “silent” cerebrovascular toxicity in cocaine dependence. Biological Psychiatry 45:1203–1211, 1999.PubMedGoogle Scholar
  110. 110.
    van Gorp, W. G., Wilkins, J. N., Hinkin, C. H., et al. Declarative and procedural memory functioning in abstinent cocaine abusers. Archives of General Psychiatry 56:85–89, 1999.PubMedGoogle Scholar
  111. 111.
    Strickland, T. L., & Stein, R. A. Neurobehavioral functioning in chronic cocaine abusers following sustained abstinence. Archives of Clinical Neurology 11:456–457, 1996.Google Scholar
  112. 112.
    Aurigemma, G. P., & Gaasch, W. H. Valve disease and diet pills—Where do we stand? American Family Physician 57:659–660, 1998.Google Scholar
  113. 113.
    Aizenstein, M. L., Segal, D. S., & Kuczenski, R. Repeated amphetamine and fencamfamine: Sensitization and reciprocal cross-sensitization. Neuropsychopharmacology 3:283–290, 1990.PubMedGoogle Scholar
  114. 114.
    Iyo, M. Pet dopamine D2 receptors and susceptibility to methamphetamine psychosis. Clinical Neuropharmacology 15:652A–653A, 1992.PubMedGoogle Scholar
  115. 115.
    Rosse, R. B., Risher-Flowers, D., Peace, T., & Deutsch, S. I. Evidence of impaired smooth pursuit eye movement performance in crack cocaine users. Biological Psychiatry 31:1238–1240, 1992.PubMedGoogle Scholar
  116. 116.
    Flaum, M., & Schultz, S. K. When does amphetamine-induced psychosis become schizophrenia? American Journal of Psychiatry 153:812–815, 1996.PubMedGoogle Scholar
  117. 117.
    Sherer, M., Kumor, K., Golden, R., & Jaffe, J. Continuous infusion of cocaine—A model for cocaine psychosis? Paper presented at the Society of Biological Psychiatry Annual Meeting, Washington, D.C., May 10, 1986.Google Scholar
  118. 118.
    Ellinwood, E. H., Jr. Assault and homicide associated with amphetamine abuse. American Journal of Psychiatry 127:1170–1176, 1971.PubMedGoogle Scholar
  119. 119.
    Perkins, K. A., Simpson, J. C., & Tsuang, M. T. Ten-year follow-up of drug abusers with acute or chronic psychosis. Hospital and Community Psychiatry 37:481–484, 1986.PubMedGoogle Scholar
  120. 120.
    Goodwin, D. W., & Guze, S. B. Psychiatric diagnosis (5th ed.). New York: Oxford University Press, 1994.Google Scholar
  121. 121.
    Siegel, R. K. Cocaine hallucinations. American Journal of Psychiatry 135:309–314, 1978.PubMedGoogle Scholar
  122. 122.
    Roberts, D. C., Dalton, J. C., & Vickers, G. J. Increased self-administration of cocaine following haloperi-dol: Effects of ovariectomy, estrogen replacement, and estrous cycle. Pharmacology, Biochemistry, and behavior 26:37–43, 1987.PubMedGoogle Scholar
  123. 123.
    Kumor, K., Sherer, M., & Jaffe, J. Haloperidol-induced dystonia in cocaine addicts. Lancet 2:1341–1342, 1986.PubMedGoogle Scholar
  124. 124.
    Gold, M. S. Cocaine (and crack): Clinical aspects. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 205–221.Google Scholar
  125. 125.
    Vincent, N., Shoobridge, J., Ask, A., et al. Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug and Alcohol Review 17:187–195, 1998.PubMedGoogle Scholar
  126. 126.
    Hall, W., Hando, J., Darke, S., & Ross, J. Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 91:81–87, 1996.PubMedGoogle Scholar
  127. 127.
    Aronson, T. A., & Craig, T. J. Cocaine precipitation of panic disorder. American Journal of Psychiatry 145:643–645, 1986.Google Scholar
  128. 128.
    Rosse, R. B., Fay-McCarthy, M., Collins, J. P., et al. Transient compulsive foraging behavior associated with crack cocaine use. American Journal of Psychiatry 150:155–156, 1993.PubMedGoogle Scholar
  129. 129.
    Gillin, J. C., Pulvirenti, L., Withers, N., et al. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: A preliminary report. Biological Psychiatry 35:843–849, 1994.PubMedGoogle Scholar
  130. 130.
    Schuckit, M. A., Tipp, J. E., Bucholz, K. K., et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 92:1289–1304, 1997.PubMedGoogle Scholar
  131. 131.
    Lange, R. A., Cigarroa, R. G., Yancy, C. W., et al. Cocaine-induced coronary-artery vasoconstriction. The New England Journal of Medicine 321:1557–1562, 1989.PubMedGoogle Scholar
  132. 132.
    Dow-Edwards, D. Fetal and maternal cocaine levels peak rapidly following intragastric administration in the rat. Journal of Substance Abuse 2:427–437, 1990.PubMedGoogle Scholar
  133. 133.
    Hulse, G. K., English, D. R., Milne, E., et al. Maternal cocaine use and low birth weight newborns: A metaanalysis. Addiction 92:1561–1570, 1997.PubMedGoogle Scholar
  134. 134.
    Vogel, G. Cocaine wreaks subtle damage on developing brains. Science 278:38–39, 1997.PubMedGoogle Scholar
  135. 135.
    Budd, R. D. Cocaine abuse and violent death. American Journal of Drug and Alcohol Abuse 15:375–382, 1989.PubMedGoogle Scholar
  136. 136.
    Boyer, C. S., & Petersen, D. R. Potentiation of cocaine-mediated hepatotoxicity by acute and chronic ethanol. Alcoholism: Clinical and Experimental Research 14:28–31, 1990.Google Scholar
  137. 137.
    Teoh, S. K., Woods, B. T., Anfinsen, P., et al. Pituitary volume in opioid and cocaine dependent men. Paper presented at the ACNP Annual Meeting, San Juan, December 10, 1991.Google Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Marc A. Schuckit
    • 1
  1. 1.University of California Medical School and Veterans Affairs San Diego Healthcare SystemSan DiegoUSA

Personalised recommendations